scispace - formally typeset
M

Mirela Foresti Jiménez

Researcher at Universidade Federal de Ciências da Saúde de Porto Alegre

Publications -  14
Citations -  659

Mirela Foresti Jiménez is an academic researcher from Universidade Federal de Ciências da Saúde de Porto Alegre. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 6, co-authored 11 publications receiving 566 citations.

Papers
More filters
Journal ArticleDOI

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

Stella G. Muthuri, +87 more
TL;DR: There was an increase in the mortality hazard rate with each day's delay in initiation of treatment up to day 5 as compared with treatment initiated within 2 days of symptom onset, and early treatment versus no treatment was also associated with a reduction in mortality risk.
Journal ArticleDOI

Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: An individual participant data meta-analysis

Stella G. Muthuri, +86 more
TL;DR: The objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1)pdm09 virus infection.
Journal ArticleDOI

Outcomes for pregnant women infected with the influenza A (H1N1) virus during the 2009 pandemic in Porto Alegre, Brazil

TL;DR: To study the epidemiologic characteristics and underlying conditions that place pregnant women infected with H1N1 virus at increased risk for being admitted to the intensive care unit (ICU), a large number of women are referred to the hospital.
Journal ArticleDOI

Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.

Sudhir Venkatesan, +69 more
TL;DR: When patients hospitalized with influenza are treated with NAIs, treatment initiated on admission, regardless of time since symptom onset, is associated with a reduced LoS, compared with later or no initiation of treatment.
Journal ArticleDOI

Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period

TL;DR: Evidence of the metabolic safety of the ENG implant in healthy women over a 3-year period is provided, Indeed, implant placement induces changes consistent with a lower risk of insulin resistance and dyslipidemia.